Abstract
In order to cope with the worldwide increase in the prevalence of multidrug-resistant tuberculosis and Mycobacterium avium complex (MAC) infections, a number of new antimycobacterial drugs have been or are being synthesized and developed. Development of new protocols for chemotherapy of refractory mycobacterioses is also sharing promise. In this context, one promising strategy is to devise regimens to treat patients with refractory mycobacterioses using ordinary antimycobacterial agents in combination with appropriate immunomodulators. This article deals with the following matters: an outline of the host immune response to mycobacterial pathogens, particularly in terms of mobilization of the cytokine network in response to mycobacterial infection, and adjunctive immunotherapy using (1) recombinant immunomodulating cytokines, (especially Th-1 and Th-1-like cytokines such as IFN-γ, IL-2, IL-12, IL-18 and GM-CSF), (2) inhibitors of immunosuppressive cytokines (TGF-β) and some proinflammatory tissue-damaging cytokines (TNF-α), and (3) immunomodulatory agents such as ATP and its analogs, imidazoquinoline, diethyldithiocarbamate, poloxamer, dibenzopyran, galactosylceramide, nonsteroidal anti-inflammatory drugs, Chinese traditional medicines, levamisole, synthesized mycobacterial oligoDNA, DNA vaccine expressing mycobacterial HSP65 or IL-12, and heat-killed Mycobacterium vaccae. Although adjunctive immunotherapy is fairly efficacious in treating intractable mycobacterioses, it still features serious problems and dilemmas, such as high cost, occasionally severe side effects, and, in many cases, only modest efficacy in potentiating host defense mechanisms against mycobacterial infections, primarily because of the induction of macrophage-deactivating cytokines during the course of long-term administration of adjunctive agents.
Keywords: tuberculosis, mycobacterium avium complex, multidrug-resistant, mycobacterium tuberculosis, isoniazid, rifampin
Current Pharmaceutical Design
Title: Adjunctive Immunotherapy of Mycobacterial Infections
Volume: 10 Issue: 26
Author(s): Haruaki Tomioka
Affiliation:
Keywords: tuberculosis, mycobacterium avium complex, multidrug-resistant, mycobacterium tuberculosis, isoniazid, rifampin
Abstract: In order to cope with the worldwide increase in the prevalence of multidrug-resistant tuberculosis and Mycobacterium avium complex (MAC) infections, a number of new antimycobacterial drugs have been or are being synthesized and developed. Development of new protocols for chemotherapy of refractory mycobacterioses is also sharing promise. In this context, one promising strategy is to devise regimens to treat patients with refractory mycobacterioses using ordinary antimycobacterial agents in combination with appropriate immunomodulators. This article deals with the following matters: an outline of the host immune response to mycobacterial pathogens, particularly in terms of mobilization of the cytokine network in response to mycobacterial infection, and adjunctive immunotherapy using (1) recombinant immunomodulating cytokines, (especially Th-1 and Th-1-like cytokines such as IFN-γ, IL-2, IL-12, IL-18 and GM-CSF), (2) inhibitors of immunosuppressive cytokines (TGF-β) and some proinflammatory tissue-damaging cytokines (TNF-α), and (3) immunomodulatory agents such as ATP and its analogs, imidazoquinoline, diethyldithiocarbamate, poloxamer, dibenzopyran, galactosylceramide, nonsteroidal anti-inflammatory drugs, Chinese traditional medicines, levamisole, synthesized mycobacterial oligoDNA, DNA vaccine expressing mycobacterial HSP65 or IL-12, and heat-killed Mycobacterium vaccae. Although adjunctive immunotherapy is fairly efficacious in treating intractable mycobacterioses, it still features serious problems and dilemmas, such as high cost, occasionally severe side effects, and, in many cases, only modest efficacy in potentiating host defense mechanisms against mycobacterial infections, primarily because of the induction of macrophage-deactivating cytokines during the course of long-term administration of adjunctive agents.
Export Options
About this article
Cite this article as:
Tomioka Haruaki, Adjunctive Immunotherapy of Mycobacterial Infections, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383232
DOI https://dx.doi.org/10.2174/1381612043383232 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Adenylation Domain Enzymology in Nonribosomal Peptide Biosynthesis
Current Organic Chemistry A New Catalytic Method for Eco-Friendly Synthesis of Quinoxalines by Zirconium (IV) Oxide Chloride Octahydrate Under Mild Conditions
Letters in Organic Chemistry The Ever Changing Face of Antibiotic Resistance: Prevailing Problems and Preventive Measures
Current Drug Metabolism Computational Biology in Anti-Tuberculosis Drug Discovery
Infectious Disorders - Drug Targets HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Current Drug Targets Tuberculosis Deaths Among Populations with High HIV Prevalence
Current Respiratory Medicine Reviews A Structural-Energetic Basis for B-Cell Epitope Prediction
Protein & Peptide Letters Lipid-based Self-Adjuvanting Vaccines
Current Drug Delivery A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches
Current Drug Targets Synthesis and Biological Evaluation of Naphthalene-1,4-dione Derivatives as Potent Antimycobacterial Agents
Medicinal Chemistry Structure of the Cytoplasmic Segment of Histidine Kinase Receptor QseC: A Key Player in Bacterial Virulence
Protein & Peptide Letters Anti-Infective Peptides to Enhance the Host Innate Response: Design, Development and Delivery
Protein & Peptide Letters Primary Isolated Mediastinal Abscess Masquerading as Mediastinal Mass- A Needle did the Trick
Current Respiratory Medicine Reviews From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders
Current Pharmaceutical Design Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Low-Cost Infertility Management
Current Women`s Health Reviews Multifocal Osteolytic Lesions in Skull Bone with Mycobacterium <i>Tuberculosis</i>: A Case Report
Infectious Disorders - Drug Targets